1. Arnold M, Morgan E, Rumgay H, Mafra A, Singh D, Laversanne M, et al. Current and future burden of breast cancer: Global statistics for 2020 and 2040. The Breast. 2022;66:15-23. [DOI:10.1016/j.breast.2022.08.010]

2. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. cell. 2011;144(5):646-74. [DOI:10.1016/j.cell.2011.02.013]

3. Strickaert A, Saiselet M, Dom G, De Deken X, Dumont JE, Feron O, et al. Cancer heterogeneity is not compatible with one unique cancer cell metabolic map. Oncogene. 2017;36(19):2637-42. [DOI:10.1038/onc.2016.411]

4. Jin H-R, Wang J, Wang Z-J, Xi M-J, Xia B-H, Deng K, et al. Lipid metabolic reprogramming in tumor microenvironment: from mechanisms to therapeutics. Journal of Hematology & Oncology. 2023;16(1):103. [DOI:10.1186/s13045-023-01498-2]

5. Schiliro C, Firestein BL. Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth and proliferation. Cells. 2021;10(5):1056. [DOI:10.3390/cells10051056]

6. Monaco ME. Fatty acid metabolism in breast cancer subtypes. Oncotarget. 2017;8(17):29487. [DOI:10.18632/oncotarget.15494]

7. Liu Y, Cao X. Characteristics and significance of the pre-metastatic niche. Cancer cell. 2016;30(5):668-81. [DOI:10.1016/j.ccell.2016.09.011]

8. Wang H, Franco F, Tsui Y-C, Xie X, Trefny MP, Zappasodi R, et al. CD36-mediated metabolic adaptation supports regulatory T cell survival and function in tumors. Nature immunology. 2020;21(3):298-308. [DOI:10.1038/s41590-019-0589-5]

9. Fichtali K, Bititi A, Elghanmi A, Ghazi B. Serum lipidomic profiling in breast cancer to identify screening, diagnostic, and prognostic biomarkers. BioResearch Open Access. 2020;9(1):1-6. [DOI:10.1089/biores.2018.0022]

10. Ni H, Liu H, Gao R. Serum lipids and breast cancer risk: a meta-analysis of prospective cohort studies. PloS one. 2015;10(11):e0142669. [DOI:10.1371/journal.pone.0142669]

11. Wu J, Lei X, Pan X, Zeng X, Li W. Association between serum lipids and breast cancer risk in premenopausal women: systematic review and meta-analysis. Journal of International Medical Research. 2021;49(11):03000605211061033. [DOI:10.1177/03000605211061033]

12. Nouri M, Mohsenpour MA, Katsiki N, Ghobadi S, Jafari A, Faghih S, et al. Effect of serum lipid profile on the risk of breast cancer: systematic review and meta-analysis of 1,628,871 women. Journal of clinical medicine. 2022;11(15):4503. [DOI:10.3390/jcm11154503]

13. Touvier M, Fassier P, His M, Norat T, Chan DS, Blacher J, et al. Cholesterol and breast cancer risk: a systematic review and meta-analysis of prospective studies. British Journal of Nutrition. 2015;114(3):347-57. [DOI:10.1017/S000711451500183X]

14. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic reviews. 2015;4:1-9. [DOI:10.1186/2046-4053-4-1]

15. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. bmj. 2021;372. [DOI:10.1136/bmj.n71]

16. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European journal of epidemiology. 2010;25:603-5. [DOI:10.1007/s10654-010-9491-z]

17. Reeves BC, Deeks JJ, Higgins JP, Wells GA. Including non‐randomized studies. Cochrane handbook for systematic reviews of interventions: Cochrane book series. 2008:389-432. [DOI:10.1002/9780470712184.ch13]